Pancreatic cancer is one of the lethal cancers accounting for a large number of cancer-related deaths worldwide. In addition, pancreatic cancer is also considered to be unresponsive to the commonly used anticancer therapies. However, in a recent study published in Nature Cancer, researchers have demonstrated that a novel triple immune therapy combination significantly improved the anti-tumor response for pancreatic cancer in preclinical models.
The investigators targeted a triple combination of 41BB, LAG3, and CXCR2 in T cells that resulted in complete tumor regression by successfully reprogramming the tumor microenvironment and improved overall survival in 90% of preclinical models. In another stringent lab model of multiple spontaneously arising tumors with higher resistance to treatment, the triple combination therapy achieved complete tumor regression in over 20% of cases. These…
